This is illustrated by the promising results of IMbrave050, a Phase III global, multicenter, open-label, randomized study assessing the impact of anti-PD-L1 and anti-VEGF on recurrence when given as an adjuvant for early-stage HCC [129]; interim results showed a significant improvement in recurrence-free survival using this combinatorial immunotherapy post resection or ablation [130]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.